# A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C

> **NCT00630058** · PHASE1 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 20 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** MP-424(H), PEG-IFN-a-2b, RBV
- **DRUG:** MP-424 (L), PEG-IFN-a-2b, RBV

## Key facts

- **NCT ID:** NCT00630058
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00630058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00630058, "A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00630058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*